Bisphosphonate induced osteonecrosis of the jaw masquerading as tumor: A word of caution for oral surgeons and oncologists

European Journal of Surgical Oncology

Volumn 36, Issue 6, 2010, Pages 541-545

  Chaturvedi, P ^a   Pai, P S ^a   Chaukar, D A ^a   Gupta, S ^a   D'cruz, A K ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Bisphosphonate; Jaw; Mandible; Necrosis; Osteonecrosis of jaw

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; BONE BIOPSY; BONE METASTASIS; BREAST CANCER; CANCER PAIN; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; DENTIST; DIAGNOSTIC ERROR; DISEASE COURSE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; JAW OSTEONECROSIS; JAW RADIOGRAPHY; JAW TUMOR; MALE; MOUTH CAVITY; MOUTH EXAMINATION; MULTIPLE MYELOMA; PAGET BONE DISEASE; PATIENT COUNSELING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; QUALITY OF LIFE; RADIOLOGIST; TOOTH EXTRACTION;

AGED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; JAW DISEASES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OSTEONECROSIS; OSTEOPOROSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS;

EID: 77953122197     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2009.12.003     Document Type: Article

References (15)

1. Ruggiero S.L., Mehrotra B., and Rosenberg T.J. Osteonecrosis of the jaws associated with the use of bisphosphonates; a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534
2. Woo S.B., Hellstein J.W., and Kalmar J.R. Systematic review: bisphosphonates and osteonecrosis of the jaw. Ann Int Med 144 (2006) 753-761
3. Berenson J.R., Lichtenstein A., Porter L., et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334 (1996) 488-493
4. Hortobagyi G.N., Theriault R.L., Porter L., et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335 (1996) 1785-1791
5. Glass D.A., Patel M.S., and Karsenty G. A new insight into the formation of osteolytic lesions in multiple myeloma. N Engl J Med 349 (2003) 2479-2480
6. Ruggiero S., Gralow J., Marx R., et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2 (2006) 7-14
7. Bannias A., Kastritis E., Bannia C., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23 (2006) 8580-8587
8. Badros A., Weikei D., Salama A., et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24 (2006) 945-952
9. Pozzi S., Marcheselli R., Sacchi S., et al. Analysis of frequency and risk factors for developing bisphosphonate associated osteonecrosis of the jaw. Blood 106 (2005) 5057a
10. Durie G.M., Katz M., and Crowley J. Osteonecrosis of the jaw and bisphosphonates (correspondence). N Engl J Med 3531 (2005) 99-102
11. Tosi P., Zamagni E., Cangini D., et al. Bisphosphonates and osteonecrosis of the jaws: incidence in a homogenous series of patients with newly diagnosed multiple myeloma treated with zoledronic acid. Blood 106 (2005) 3461a
12. Mehrotra B. Safety profile of intravenous bisphosphonates. Semin Oncol 34 Suppl. 4 (2007 Dec) S24-S27
13. Lacy M., Dispenzieri A., Gertz M., et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 81 (2006) 1047-1053
14. Thakkar S., Isada C., Smith J., et al. Jaw complications associated with bisphosphonates use in patients with plasma cell dyscrasias. Med Oncol 23 (2006) 51-56
15. Rosen L.S., Gordon D., Kaminski M., et al. Long term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer 98 (2003) 1735-1744